Focus on primary care postmenopausal osteoporosis: An update

Obstetrical and Gynecological Survey

Volumn 55, Issue 12 SUPPL. 3, 2000, Pages

  Watts, N B ^a  

^a EMORY CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; CALCIUM; ESTROGEN; RALOXIFENE; RISEDRONIC ACID; VITAMIN D;

BONE ATROPHY; BONE DENSITY; BONE MINERAL; BONE REMODELING; DRUG APPROVAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY MEDICAL CARE; REVIEW; VERTEBRA FRACTURE;

BONE DENSITY; CALCITONIN; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 0033675229     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-200012001-00001     Document Type: Review

References (64)

1. Postmenopausal osteoporosis
2. Prophylaxis and treatment of osteoporosis
3. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the national osteoporosis foundation
4. How to get the most out of bone densitometry
5. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?
6. Discordance in patient Classification using T-scores
7. Monitoring osteoporosis therapy with bone densitometry-Misleading changes and regression to the mean
8. Monitoring osteoporosis therapy with bone densitometry: A vital tool or regression toward mediocrity
9. Regression to the mean: Additional considerations for monitoring with DXA
10. The diagnosis of osteoporosis
11. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
12. Physician's guide to prevention and treatment of osteoporosis
13. Prediction of fracture risk. 2. Other risk factors
14. Risk factors for hip fracture in white women
15. Clinical use of biochemical markers of bone remodeling: Current status and future directions
16. Application of a new serum assay for type I collagen cross-linked N-telopeptides: Assessment of diurnal change in bone turnover with and without alendronate treatment
17. Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy
18. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis
19. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
20. Alendronate in early postmenopausal women: Effects on bone mass during long-term treatment and after withdrawal
21. Risedronic acid. NE 58095, risedronate sodium, Actonel
22. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis - A randomized controlled trial
23. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
24. Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis
25. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density
26. Risedronate prevents bone loss in early postmenopausal women
27. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
28. Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after 7 years of treatment
29. Nasal calcitonin for treatment of established osteoporosis
30. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study
31. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
32. Treatment of postmenopausal osteoporosis with transdermal estrogen
33. Effects of hormone therapy on bone mineral density - Results from the post-menopausal estrogen/progestin interventions (PEPI) trial
34. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen
35. Estrogen replacement therapy and fractures in older women
36. Timing of post-menopausal estrogen for optimal bone mineral density - The Rancho Bernardo study
37. Bone response to termination of oestrogen treatment
38. Hormone therapy to prevent disease and prolong life in postmenopausal women
39. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
40. Effects of estrogen replacement of the progression of coronary artery atherosclerosis
41. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease - A randomized controlled trial
42. Continuation of postmenopausal hormone replacement therapy: Comparison of cyclic versus continuous combined schedules
43. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
44. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial
45. The effect of raloxifene on risk of breast cancer in postmenopausal women - Results from the MORE randomized trial
46. Alendronate and estrogen effects in postmenopausal women with low bone mineral density
47. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: A randomized, controlled clinical trial
48. The effects of risedronate plus estrogen compared with estrogen alone in postmenopausal women
49. Effects of raloxifene (RLX), alendronate (ALN), and RLX+ALN on bone mineral density (BMD) and biochemical markers of bone turnover in post-menopausal women with osteoporosis
50. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis
51. Ibandronate
52. Zoledronate
53. A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial
54. Recombinant human PTH [rhPTH(1-34)] reduces the risk of spine and non-spine fractures in postmenopausal osteoporosis
55. The pharmacology of bisphosphonates and new insights into their mechanisms of action
56. Stimulation of bone formation in vitro and in rodents by statins
57. HMG-CoA reductase inhibitors and the risk of hip fractures inelderly patients
58. HMG-CoA reductase inhibitors and the risk of fractures
59. Effect of augmentation on the mechanics of vertebral wedge fractures
60. Percutaneous vertebroplasty with polymethylmethacrylate. Technique, indications, and results